Lyell Immunopharma, Inc.
LYEL · NASDAQ
Market closed$13.32$-0.570000 (-4.10%)After hours $13.60 · +2.10%
Key statistics
Previous close$13.89
Open$13.81
Day high$13.90
Day low$13.06
52-week high$45.00
52-week low$9.28
Market cap326.40M
Volume168.67K
Average volume150.33K
P/E ratio-0.97
Forward P/E—
EPS-13.80
Dividend yield0.00%
Market context
Why it moved
Lyell Immunopharma (LYEL) shares declined amid broader biotech sector weakness, with limited company-specific catalysts as attention around the stock centered on CEO Lynn Seely's appointment to AbCellera's board, potentially raising concerns about management focus and resource allocation at Lyell.
What is happening
Recent company-specific developments and publisher coverage.
Stock Titan · June 12, 2026Over 100 lymphoma patients get CAR-T with no Grade 3+ CRSStock Titan · June 4, 2026Lyell CAR T study reports low-grade side effects in lymphomaGlobeNewswire · May 6, 2026Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026GlobeNewswire · March 9, 2026Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business OfficerGlobeNewswire · February 12, 2026Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell LymphomaQuiver Quantitative · December 7, 2025Lyell Immunopharma Reports Promising Efficacy Data for Rondecabtagene Autoleucel in Large B-Cell Lymphoma TrialsQuiver Quantitative · July 25, 2025Lyell Immunopharma, Inc. Secures $100 Million in Private Placement to Advance CAR T-Cell Therapy Trials Mt Newswire · July 13, 2026Lyell Immunopharma Files for Secondary Offering of Common Shares Benzinga · June 15, 2026Citizens Reiterates Market Outperform on Lyell Immunopharma, Maintains $34 Price Target Benzinga · June 15, 2026Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target Benzinga · June 12, 2026Lyell Immunopharma Announces Data From Its Phase 1/2 Clinical Study Of Rondecabtagene Autoleucel In Participants With Relapsed Or Refractory Large B-cell Lymphoma Shows Manufacturing Success Rate Of 97% Benzinga · June 8, 2026Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target Benzinga · June 8, 2026Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update Mt Newswire · June 8, 2026Lyell Immunopharma's Cancer Therapy Shows Improved Safety in Phase 1 Study Benzinga · June 8, 2026Lyell Immunopharma Issues LYL273 Safety Profile Update In Its Ongoing U.S. Phase 1 Clinical Trial In Patients With Relapsed Or Refractory Metastatic Colorectal Cancer